| Drug-Target Information | ||||||||
|---|---|---|---|---|---|---|---|---|
| Drug Name | Target Name | Drug Type | Target Type | Source | Drug MeSHID | Interaction Score | Drug Status | Target Action |
| r-roscovitine | cyclin-dependent kinase 1 | NA | Clinical trial target | TTD , DGIDB | Non-Small Cell Lung Carcinoma[MeSHID:D002289] Malignant Neoplasms[MeSHID:D009369] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Nasopharyngeal carcinoma[MeSHID:C538339] |
0.29 | phase 2 | unknown |
| r-roscovitine | cyclin-dependent kinase 2 | NA | Clinical trial target | TTD , DGIDB | Non-Small Cell Lung Carcinoma[MeSHID:D002289] Malignant Neoplasms[MeSHID:D009369] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Nasopharyngeal carcinoma[MeSHID:C538339] |
0.61 | phase 2 | unknown |
| r-roscovitine | cyclin-dependent kinase 7 | NA | Clinical trial target | TTD , DGIDB | Non-Small Cell Lung Carcinoma[MeSHID:D002289] Malignant Neoplasms[MeSHID:D009369] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Nasopharyngeal carcinoma[MeSHID:C538339] |
1.02 | phase 2 | unknown |
| click here to return to the previous page | ||||||||